Meeting
2020 Gastrointestinal Cancers Symposium
Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition.
Authors
Katherine M. Bever
The Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD
Katherine M. Bever , Hao Wang , Jennifer N. Durham , Susan Petrie , Jessica Hoare , Cara Wilt , William Howard Sharfman , Nilofer Saba Azad , Daniel A. Laheru , Robert A Anders , Drew M. Pardoll , Suzanne Louise Topalian , Elizabeth M. Jaffee , Dung T. Le
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03607890
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS839)
Abstract #
TPS839
Poster Bd #
L20
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
First Author: Anthony B. El-Khoueiry
Poster
2023 ASCO Gastrointestinal Cancers Symposium
LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).
First Author: Kai Tsugaru
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek